Literature DB >> 2272367

Analgesia produced by intrathecal administration of the kappa opioid agonist, U-50,488H, on formalin-evoked cutaneous pain in the rat.

T Pelissier1, C Paeile, R Soto-Moyano, H Saavedra, A Hernández.   

Abstract

The antinociceptive activity of the selective kappa opioid agonist U-50,488H, given intrathecally (i.t.) against chemically induced cutaneous pain in rats, was assessed from cumulative dose-response experiments and the formalin test. Three successive i.t. doses of 5, 10 and 35 nmol of U-50,488H produced a gradual reduction of pain scores which was statistically significant at all observation periods. This effect was antagonized significantly by 3 mg/kg i.p. of the opiate antagonists, naloxone and WIN 44,441-3. The analgesia profile showed a clear dose-response relationship. A dose producing 50% 'maximum possible analgesia' of 6.20 nmol (95% confidence interval: 3.05-12.59 nmol) was calculated. The results indicated that cutaneous pain of a chemical/inflammatory nature is highly sensitive to activation of kappa receptors of the spinal cord dorsal horn.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2272367     DOI: 10.1016/0014-2999(90)94192-z

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

1.  GR94839, a kappa-opioid agonist with limited access to the central nervous system, has antinociceptive activity.

Authors:  H Rogers; P J Birch; S M Harrison; E Palmer; G R Manchee; D B Judd; A Naylor; D I Scopes; A G Hayes
Journal:  Br J Pharmacol       Date:  1992-08       Impact factor: 8.739

2.  Estrogens as arbiters of sex-specific and reproductive cycle-dependent opioid analgesic mechanisms.

Authors:  Alan R Gintzler; Emiliya M Storman; Nai-Jiang Liu
Journal:  Vitam Horm       Date:  2019-07-02       Impact factor: 3.421

3.  Spinal astrocytes produce and secrete dynorphin neuropeptides.

Authors:  Andrew Wahlert; Lydiane Funkelstein; Bethany Fitzsimmons; Tony Yaksh; Vivian Hook
Journal:  Neuropeptides       Date:  2013-01-03       Impact factor: 3.286

Review 4.  Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects.

Authors:  Kelly F Paton; Diana V Atigari; Sophia Kaska; Thomas Prisinzano; Bronwyn M Kivell
Journal:  J Pharmacol Exp Ther       Date:  2020-09-10       Impact factor: 4.030

5.  Effects of acute agonist treatment on subcellular distribution of kappa opioid receptor in rat spinal cord.

Authors:  Yulin Wang; Wei Xu; Peng Huang; Charles Chavkin; Elisabeth J Van Bockstaele; Lee-Yuan Liu-Chen
Journal:  J Neurosci Res       Date:  2009-05-15       Impact factor: 4.164

6.  Central and peripheral actions of the novel kappa-opioid receptor agonist, EMD 60400.

Authors:  A Barber; G D Bartoszyk; H E Greiner; F Mauler; R D Murray; C A Seyfried; M Simon; R Gottschlich; J Harting; I Lues
Journal:  Br J Pharmacol       Date:  1994-03       Impact factor: 8.739

7.  Evaluation of Antinociceptive Effects of Chitosan-Coated Liposomes Entrapping the Selective Kappa Opioid Receptor Agonist U50,488 in Mice.

Authors:  Liliana Mititelu Tartau; Maria Bogdan; Beatrice Rozalina Buca; Ana Maria Pauna; Cosmin Gabriel Tartau; Lorena Anda Dijmarescu; Eliza Gratiela Popa
Journal:  Medicina (Kaunas)       Date:  2021-02-04       Impact factor: 2.430

8.  Warming Moxibustion Relieves Chronic Visceral Hyperalgesia in Rats: Relations to Spinal Dynorphin and Orphanin-FQ System.

Authors:  Li Qi; Hui-Rong Liu; Tao Yi; Lu-Yi Wu; Xi-Ru Liu; Chen Zhao; Yin Shi; Xiao-Peng Ma; Huan-Gan Wu
Journal:  Evid Based Complement Alternat Med       Date:  2013-03-16       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.